Shanghai Shyndec Pharmaceutical Co Ltd Total Liabilities
Shanghai Shyndec Pharmaceutical Co Ltd total liabilities. Based on the latest financial reports, Shanghai Shyndec Pharmaceutical Co Ltd (600420) has total liabilities worth CN¥3.44 Billion CNY (≈ $503.54 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Shanghai Shyndec Pharmaceutical Co Ltd (600420) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Shanghai Shyndec Pharmaceutical Co Ltd (2001–2025)
Total liabilities of Shanghai Shyndec Pharmaceutical Co Ltd from 2001 to 2025. This chart illustrates how Shanghai Shyndec Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore 600420 long-term investments to assets to see how much of total assets are deployed in long-term investments.
Shanghai Shyndec Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Shanghai Shyndec Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Neinor Homes SLU
MC:HOME
|
Spain | €2.42 Billion |
|
Changjiang Publishing & Media Co Ltd
SHG:600757
|
China | CN¥3.73 Billion |
|
Dime Community Bancshares, Inc.
NASDAQ:DCOM
|
USA | $13.50 Billion |
|
Opple Lighting Co Ltd
SHG:603515
|
China | CN¥2.57 Billion |
|
FRIEDR.VORW.GRP. ADR/025
F:VH20
|
Germany | €210.59 Million |
|
Suzhou Crystal Clear Chemical Co Ltd
SHE:300655
|
China | CN¥1.45 Billion |
|
Sichuan Tuopai Shede Wine Co Ltd
SHG:600702
|
China | CN¥5.74 Billion |
|
Hamburger Hafen und Logistik Aktiengesellschaft
F:HHFA
|
Germany | €2.64 Billion |
Liability Composition Analysis (2001–2025)
This chart breaks down Shanghai Shyndec Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Shanghai Shyndec Pharmaceutical Co Ltd.
Liquidity & Leverage Metrics
Shanghai Shyndec Pharmaceutical Co Ltd Total Liabilities Ratios Explained
Shanghai Shyndec Pharmaceutical Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.25 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shanghai Shyndec Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shanghai Shyndec Pharmaceutical Co Ltd (2001–2025)
The table below shows the annual total liabilities of Shanghai Shyndec Pharmaceutical Co Ltd from 2001 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥-15.70 Billion ≈ $-2.30 Billion |
-438.80% |
| 2024-12-31 | CN¥4.63 Billion ≈ $678.05 Million |
-7.59% |
| 2023-12-31 | CN¥5.01 Billion ≈ $733.72 Million |
-32.95% |
| 2022-12-31 | CN¥7.48 Billion ≈ $1.09 Billion |
-14.05% |
| 2021-12-31 | CN¥8.70 Billion ≈ $1.27 Billion |
+3.19% |
| 2020-12-31 | CN¥8.43 Billion ≈ $1.23 Billion |
-0.05% |
| 2019-12-31 | CN¥8.44 Billion ≈ $1.23 Billion |
+5.17% |
| 2018-12-31 | CN¥8.02 Billion ≈ $1.17 Billion |
+6.62% |
| 2017-12-31 | CN¥7.52 Billion ≈ $1.10 Billion |
-6.86% |
| 2016-12-31 | CN¥8.08 Billion ≈ $1.18 Billion |
+219.77% |
| 2015-12-31 | CN¥2.53 Billion ≈ $369.60 Million |
+4.50% |
| 2014-12-31 | CN¥2.42 Billion ≈ $353.69 Million |
+32.78% |
| 2013-12-31 | CN¥1.82 Billion ≈ $266.38 Million |
+42.41% |
| 2012-12-31 | CN¥1.28 Billion ≈ $187.06 Million |
+134.68% |
| 2011-12-31 | CN¥544.70 Million ≈ $79.71 Million |
+82.76% |
| 2010-12-31 | CN¥298.05 Million ≈ $43.61 Million |
+39.12% |
| 2009-12-31 | CN¥214.24 Million ≈ $31.35 Million |
+31.11% |
| 2008-12-31 | CN¥163.41 Million ≈ $23.91 Million |
+36.66% |
| 2007-12-31 | CN¥119.57 Million ≈ $17.50 Million |
+38.80% |
| 2006-12-31 | CN¥86.15 Million ≈ $12.61 Million |
-19.24% |
| 2005-12-31 | CN¥106.67 Million ≈ $15.61 Million |
+43.54% |
| 2004-12-31 | CN¥74.32 Million ≈ $10.87 Million |
-37.60% |
| 2003-12-31 | CN¥119.11 Million ≈ $17.43 Million |
+33.98% |
| 2002-12-31 | CN¥88.90 Million ≈ $13.01 Million |
+10.19% |
| 2001-12-31 | CN¥80.67 Million ≈ $11.81 Million |
-- |
About Shanghai Shyndec Pharmaceutical Co Ltd
Shanghai Shyndec Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in China. The company provides nifedipine controlled release tablets, penicillin industrial potassium salt, touboke yuekui granules/capsules, sodium cefuroxime for injection, D-7ACA, fermented products, milnacipran hydrochloride tablets, compound licorice tablets, and… Read more